Additionally, benefit for prostate RT on OS and FFS within patients with low-burden disease was consistent across age, pre-ADT PSA level, World Health Organization performance status, Gleason score, tumor stage, regional nodal stage, nominated RT schedule, or planned docetaxel use (all interaction P > .10; supporting data reported in eFigure 5 and eFigure 6 in Supplement 2). Here, KLK3 is linked to neoplasm.